These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 23939265

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C.
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [Abstract] [Full Text] [Related]

  • 23. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, Uslu I, Kanmaz B.
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.
    Klingenstein A, Haug AR, Miller C, Hintschich C.
    Orbit; 2015 Feb; 34(1):16-22. PubMed ID: 25264824
    [Abstract] [Full Text] [Related]

  • 26. Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
    Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, Van Herpe F, Jaekers J, Cleeren F, Hofland J, Brouwers A, Koole M, Bormans G, Van Cutsem E, Geboes K, Laenen A, Verslype C, Stroobants S, Deroose CM.
    J Neuroendocrinol; 2024 Aug; 36(8):e13420. PubMed ID: 38837825
    [Abstract] [Full Text] [Related]

  • 27. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
    Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, Tan T, Rubello D, Al-Nahhas A.
    Mol Imaging Biol; 2011 Aug; 13(4):769-75. PubMed ID: 20700766
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
    Velikyan I, Xu H, Nair M, Hall H.
    Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
    Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, Beiderwellen K, Bockisch A, Rosenbaum-Krumme SJ.
    J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Patnecha M, Lata S, Kumar R, Malhotra A, Bal C.
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [Abstract] [Full Text] [Related]

  • 35. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP.
    Cancer Biother Radiopharm; 2007 Jun; 22(3):406-16. PubMed ID: 17651048
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S, Lind P.
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [Abstract] [Full Text] [Related]

  • 38. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE.
    Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, Li N, Yu J, Yang Z.
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
    [Abstract] [Full Text] [Related]

  • 39. The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin.
    Kazmierczak PM, Rominger A, Wenter V, Spitzweg C, Auernhammer C, Angele MK, Rist C, Cyran CC.
    Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
    [Abstract] [Full Text] [Related]

  • 40. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).
    Pałyga I, Kowalska A, Gąsior-Perczak D, Tarnawska-Pierścińska M, Słuszniak J, Sygut J, Góźdź S.
    Endokrynol Pol; 2010 Apr; 61(5):507-11. PubMed ID: 21049467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.